News

Obesity drugmaker Novo Nordisk picks Maziar Mike Doustdar as new CEO
Novo Nordisk named Maziar Mike Doustdar as its new chief executive on Tuesday, relying on an experienced company insider to ...
Novo Nordisk Cuts Earning Forecasts Again, Names New CEO
Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday ...
Novo Nordisk outgoing CEO blames compounded GLP-1s for decline in 2025 outlook
Novo Nordisk's downward guidance Tuesday sent its stock diving 20%, even as new leadership remains bullish on the company's ...
Novo Nordisk Cut Its Outlook and Named a New CEO. Its Stock Is Plummeting
U.S.-listed shares of Novo Nordisk sank in premarket trading Tuesday after the Danish drugmaker cut its full-year outlook and ...
NVO stock: Why did Novo Nordisk shares drop 20% today—and who is Maziar Mike Doustdar?
Partially a result, Novo Nordisk has steadily declined since last summer. Over the past year, NVO shares are down more than ...
Novo Nordisk appoints new CEO Maziar Doustdar
July 29 (UPI) -- Novo Nordisk announced Tuesday that Mike Doustdar has been appointed as the company's new CEO. Doustdar ...
Novo Nordisk faces 'show me' moment to boost Wegovy growth after US copycat ban
A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...
Weight-loss patients taking Zepbound forced to switch to Wegovy after drop in coverage
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...